Genetic and specialty testing programs for inherited and acquired heart conditions
Cardiology conditions+Cardiology includes sponsored testing programs that offer no-cost or low-cost access to genetic and specialty testing for cardiomyopathy, arrhythmias, lipid disorders, and other hereditary or acquired cardiac conditions. These programs help identify underlying genetic risks, inform treatment and family screening decisions, and connect patients and clinicians with available sponsored testing options that support early diagnosis and proactive cardiac care.
9 programs found in Cardiology
The Alnylam Act® program supports eligible patients in the U.S. and Canada with no-cost access to genetic testing and counseling for acute hepatic porphyria (AHP), facilitating diagnostic clarity in this rare metabolic condition. Services are delivered by independent third-party providers and governed under a strict policy of de-identified data sharing for research purposes.
This Inozyme Pharma–sponsored program offers no-cost testing for ENPP1 and ABCC6, genes associated with GACI type 1 and later manifestations such as ARHR2 or PXE. Genetic confirmation supports diagnosis, management decisions, and assessment of family risk.
Sponsored by Biogen, this program offers no-cost genetic testing for Friedreich ataxia (FA) to support diagnosis and evaluation of patients with suspected or confirmed FA. Testing is available for individuals ≥16 years residing in the U.S. or Puerto Rico and must be ordered by a qualified provider.
The Invitae Unlock™ Cardiomyopathy & Arrhythmia program offers no-charge genetic testing for U.S. patients with suspected inherited cardiomyopathy or arrhythmia. The comprehensive panel supports diagnostic clarification, risk assessment, and family variant identification. Eligible patients may access testing at no cost when ordered by a qualified healthcare provider.
The Mission: Genome – Danon Disease Program offers no-charge Invitae testing for US-based patients with clinical suspicion of Danon disease. Testing includes LAMP2 as part of the Invitae Arrhythmia and Cardiomyopathy Panel. Eligible patients also receive no-charge post-test genetic counseling to support result interpretation and follow-up care.
This sponsored program provides no-cost genetic testing for adult U.S. patients with a family history of hATTR, positive PYP or biopsy findings, or red-flag symptoms concerning for hATTR. Testing includes TTR gene analysis to support diagnostic evaluation, risk assessment, and clinical decision-making in patients with suspected hereditary transthyretin amyloidosis.
The CardioNavigATTR program is a no-charge genetic testing initiative for adult U.S. patients meeting specific criteria who are at risk for hATTR or cardiomyopathy. It offers a 36-gene cardiomyopathy panel (including TTR) to support diagnostic investigation, guide clinical decision-making, and identify hereditary risk in the cardiology setting.
Sponsored by Inozyme Pharma, this program offers global, no-cost genetic testing for the ABCC6 gene linked to PXE. Testing is available for patients who meet program eligibility criteria and must be ordered by a qualified health care provider.
Roadmap2Rare (Canada) provides complimentary genetic and biochemical testing for suspected rare diseases, delivered by Revvity Omics in collaboration with Sanofi Canada. The program is designed to address unmet testing needs and is available to Canadian clinicians. Test selection and treatment decisions remain at the discretion of the healthcare professional.
